The franchise drug for autoimmune disorders such as dermatitis could face a challenger: A candidate from Apogee Therapeutics.

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...

Tremfya snagged Dupixent’s place as the pharma brand with the most TV impressions in June, according to data released by iSpot.tv on Friday morning. The Johnson & Johnson brand garnered a 4.3% share ...

Learn about side effects, cost, and more of Dupixent (dupilumab). It’s a prescription drug that treats atopic dermatitis (a type of eczema) and other conditions.

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...

On the other side, on July 7, JP Morgan analyst Chris Schott reiterated a Buy rating on Regeneron, while maintaining his $800 ...

Several companies on Wall Street have seen recent Seeking Alpha analyst activity, including both upgrades and downgrades.

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

A separate study looked at Dupixent in people who had a severe type of asthma, called corticosteroid-dependent asthma. This study included people who were 12 years and older, with an average age ...

After 6 months of treatment, people who used Dupixent were more likely to have fewer and smaller nasal polyps than the people who used a placebo. One study measured the polyps again after a year ...